Wealthcare Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.3M | Sell |
4,627
-215
| -4% | -$95.3K | 0.04% | 327 |
|
|
2026
Q1 | $2.16M | Sell |
4,842
-417
| -8% | -$194K | 0.04% | 352 |
|
|
2025
Q4 | $2.38M | Buy |
5,259
+130
| +3% | +$56K | 0.05% | 315 |
|
|
2025
Q3 | $2.01M | Buy |
5,129
+1,967
| +62% | +$822K | 0.04% | 344 |
|
|
2025
Q2 | $1.41M | Sell |
3,162
-29
| -0.9% | -$13.4K | 0.03% | 409 |
|
|
2025
Q1 | $1.55M | Sell |
3,191
-70
| -2% | -$32.6K | 0.04% | 350 |
|
|
2024
Q4 | $1.31M | Buy |
3,261
+172
| +6% | +$79.7K | 0.04% | 365 |
|
|
2024
Q3 | $1.44M | Sell |
3,089
-239
| -7% | -$115K | 0.04% | 332 |
|
|
2024
Q2 | $1.56M | Buy |
3,328
+110
| +3% | +$47.7K | 0.05% | 285 |
|
|
2024
Q1 | $1.35M | Buy |
3,218
+141
| +5% | +$59.6K | 0.04% | 304 |
|
|
2023
Q4 | $1.25M | Sell |
3,077
-41
| -1% | -$15.1K | 0.05% | 271 |
|
|
2023
Q3 | $1.08M | Sell |
3,118
-33
| -1% | -$11.5K | 0.05% | 264 |
|
|
2023
Q2 | $1.11M | Sell |
3,151
-208
| -6% | -$70.1K | 0.05% | 267 |
|
|
2023
Q1 | $1.06M | Sell |
3,359
-91
| -3% | -$27.3K | 0.05% | 279 |
|
|
2022
Q4 | $996K | Buy |
3,450
+91
| +3% | +$27.7K | 0.05% | 276 |
|
|
2022
Q3 | $973K | Buy |
3,359
+156
| +5% | +$44.9K | 0.06% | 242 |
|
|
2022
Q2 | $903K | Sell |
3,203
-281
| -8% | -$75.2K | 0.05% | 221 |
|
|
2022
Q1 | $909K | Sell |
3,484
-141
| -4% | -$33.5K | 0.06% | 210 |
|
|
2021
Q4 | $796K | Buy |
3,625
+2,185
| +152% | +$425K | 0.05% | 232 |
|
|
2021
Q3 | $261K | Buy |
1,440
+6
| +0.4% | +$1.17K | 0.02% | 455 |
|
|
2021
Q2 | $289K | Buy |
1,434
+33
| +2% | +$6.9K | 0.02% | 436 |
|
|
2021
Q1 | $301K | Buy |
+1,401
| New | +$308K | 0.02% | 395 |
|
|
2020
Q2 | – | Sell |
-107
| Closed | -$25K | – | 1336 |
|
|
2020
Q1 | $25K | Buy |
107
+4
| +4% | +$918 | ﹤0.01% | 680 |
|
|
2019
Q4 | $23K | Hold |
103
| – | – | ﹤0.01% | 736 |
|
|
2019
Q3 | $17K | Hold |
103
| – | – | ﹤0.01% | 797 |
|
|
2019
Q2 | $19K | Hold |
103
| – | – | ﹤0.01% | 739 |
|
|
2019
Q1 | $19K | Hold |
103
| – | – | ﹤0.01% | 677 |
|
|
2018
Q4 | $17K | Hold |
103
| – | – | ﹤0.01% | 669 |
|
|
2018
Q3 | $20K | Hold |
103
| – | – | ﹤0.01% | 679 |
|
|
2018
Q2 | $18K | Hold |
103
| – | – | ﹤0.01% | 702 |
|
|
2018
Q1 | $17K | Sell |
103
-3
| -3% | -$490 | ﹤0.01% | 626 |
|
|
2017
Q4 | $16K | Buy |
106
+3
| +3% | +$444 | ﹤0.01% | 581 |
|
|
2017
Q3 | $16K | Buy |
+103
| New | +$15.5K | ﹤0.01% | 466 |
|
Other funds holding VRTX
Wealthcare Advisory Partners's VRTX Position: Q2 2026 in Review
Wealthcare Advisory Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 4.4% in Q2 2026, selling an estimated $95.3K and leaving 4,627 shares worth $2.3M. The position accounts for 0.04% of the portfolio, ranked #327.
Wealthcare Advisory Partners first reported a position in VRTX in Q3 2017 and has held it in 33 quarters since. The position peaked at $2.38M in Q4 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Wealthcare Advisory Partners held 4,627 shares of Vertex Pharmaceuticals worth $2.3M as of Q2 2026.
- Wealthcare Advisory Partners sold 215 Vertex Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
- Vertex Pharmaceuticals made up 0.04% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #327 holding.
- Wealthcare Advisory Partners first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 33 quarters since.
- Wealthcare Advisory Partners's Vertex Pharmaceuticals position peaked at $2.38M in Q4 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.